We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




Single-Cell Sequencing Reveals Clonal Diversity Among AML Patients

By LabMedica International staff writers
Posted on 03 Nov 2020
A growing body of evidence supports the role of clonal diversity in therapeutic resistance, recurrence, and poor outcomes in cancer. More...
Clonal diversity also reflects the history of the accumulation of somatic mutations within a tumor.

The ability to infer clonal heterogeneity and tumor phylogeny from bulk sequencing data is inherently limited, because bulk sequencing techniques cannot reliably infer mutation co-occurrences and hence often fail in accurately reconstructing clonal substructure. Single-cell DNA sequencing (scDNA-seq) can address some of these challenges.

A large team of scientists at the University of Texas MD Anderson Cancer Center (Houston, TX, USA) analyzed 154 samples (140 bone marrow mononuclear cells (BMMCs) and 14 peripheral blood mononuclear cells) from 123 patients with acute myeloid leukemia (AML) who had at least one somatic mutation covered by the targeted panel for scDNA-seq. Of the 123 patients, 108 patients were analyzed for the single-timepoint sample collected at pre-treatment (N = 98) or relapsed/refractory timepoint (N = 10). Among 123 patients, 97 were analyzed by scDNA-seq, 23 were analyzed by the simultaneous single-cell DNA and cell surface protein sequencing (scDNA+protein-seq), and three were analyzed by scDNA-seq and scDNA+protein-seq.

The pooled library was sequenced by one of the following sequencing platforms, MiSeq, HiSeq 4000, or NovaSeq 6000 (Illumina, Sand Diego, CA, USA) with 150- or 250-base pair (bp) paired-end multiplexed runs. The team performed droplet digital PCR (ddPCR) using QX200 Droplet Digital System (Bio-Rad Laboratories, Hercules, CA, USA) to confirm the variants that were detected by scDNA-seq, but were not detected by bulk-seq. Simultaneous profiling of DNA mutation and cell-surface immunophenotype (scDNA+protein-seq) was performed using the custom-designed panel kit and 10–15 oligo-conjugated antibodies (Mission Bio, South San Francisco, CA, USA). Immunophenotypes of the bone marrow cells from AML patients were assessed using eight-color flow cytometry on FACSCanto II (BD Biosciences, San Jose, CA, USA).

In all, the scientists sequenced more than 730,000 cells to find 543 somatic mutations in 31 cancer-related genes, 98% of which they orthogonally validated. The most common mutations they detected were in NPM1, followed by ones in DNMT3A and NRAS. They further found that while a number of mutations that were functionally redundant were found in the same patients, the alterations were often found in mutually exclusive clones. This extended to alterations affecting receptor tyrosine kinase (RTK)/Gas GTPase (RAS)/MAP kinase (MAPK) signaling pathway genes as well as IDH1 and IDH2 mutations and TET2 and IDH mutations. This suggested to the scientists that cells either do not need two mutations or that, when they appear together, the mutations are toxic, which could suggest a potential treatment avenue to investigate.

The investigators also analyzed genotype-phenotype correlations among the cells to find, for instance, that cells with NPM1 or IDH mutations expressed lower levels of CD34 and HLA-DR, while cells with a single TP53 mutations had CD34+CD117+ phenotype, but double TP53 mutations had a monocytic immunophenotype.

Koichi Takahashi, MD, PhD, the senior author of the study, said, “This information is also somewhat available from longitudinal bulk sequencing data longitudinally, but I think single-cell data uniquely provides this meticulous view of clone-by-clone dynamics, which is just simply not possible by bulk sequencing.” The study was published on October 21, 2020 in the journal Nature Communications.



New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Clostridium Difficile Toxin A+B Combo Card Test
CerTest Clostridium Difficile Toxin A+B
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.